# Lyell Immunopharma, Inc. (LYEL) — Operating Income

## Annual Operating Income (USD)

| Year | Operating Income |
| --- | --- |
| 2025 | -$269M |
| 2024 | -$359M |
| 2023 | -$247M |
| 2022 | -$187M |
| 2021 | -$215M |
| 2020 | -$212M |
| 2019 | -$102M |

## Quarterly Operating Income (USD)

| Quarter | Operating Income |
| --- | --- |
| 2026-03-31 | -$44M |
| 2025-09-30 | -$37M |
| 2025-06-30 | -$47M |
| 2025-03-31 | -$57M |
| 2024-09-30 | -$51M |
| 2024-06-30 | -$52M |
| 2024-03-31 | -$56M |
| 2023-09-30 | -$59M |
| 2023-06-30 | -$66M |
| 2023-03-31 | -$63M |
| 2022-09-30 | -$66M |
| 2022-06-30 | -$37M |
| 2022-03-31 | -$69M |
| 2021-09-30 | -$49M |
| 2021-06-30 | -$63M |
| 2021-03-31 | -$55M |
| 2020-09-30 | -$37M |
| 2020-06-30 | -$103M |

Source: [MarketCapTrends](https://marketcaptrends.com/company/LYEL/operating-income)